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Abstract
Background: Molecular epidemiological definitions that are based on staphylococcal cassette chromosome mec (SCCmec)
typing and phylogenetic analysis of methicillin-resistant Staphylococcus aureus (MRSA) isolates are considered a reliable
way to distinguish between healthcare-associated MRSA (HA-MRSA) and community-associated MRSA (CA-MRSA). However,
there is little information regarding the clinical features and outcomes of bacteremia patients with MRSA carrying different
SCCmec types.
Methods: From January 1 through December 31, 2006, we recorded the demographic data and outcomes of 159
consecutive adult MRSA bacteremia patients from whom isolates for SCCmec analysis were collected. All participants were
patients at a tertiary care center in Taiwan.
Principal Findings: The following SCCmec types were identified in MRSA isolates: 30 SCCmec II (18.9%), 87 SCCmec III
(54.7%), 22 SCCmec IV (13.8%), and 20 SCCmec V (12.6%). The time from admission to the first MRSA-positive blood culture
for patients infected with isolates with the SCCmec III element (mean/median, 50.7/26 days) was significantly longer than for
patients infected with isolates carrying SCCmec IV or V (mean/median, 6.7/3 days for SCCmec IV; 11.1/10.5 days for SCCmec
V) (P,0.05). In univariate analysis, community onset, soft tissue infection, and deep-seated infection were predictors for
SCCmec IV/V. In multivariate analysis, length of stay before index culture, diabetes mellitus, and being bedridden were
independent risk factors associated with SCCmec II/III.
Conclusions: These findings are in agreement with previous studies of the genetic characteristics of CA-MRSA. MRSA
bacteremia with SCCmec II/III isolates occurred more among patients with serious comorbidities and prolonged
hospitalization. Community onset, skin and soft tissue infection, and deep-seated infection best predicted SCCmec IV/V
MRSA bacteremia.
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Introduction
Community-associated methicillin-resistant Staphylococcus aureus
(CA-MRSA) has been isolated mainly from skin or soft tissue
infections [1,2], although severe invasive infections caused by CA-
MRSA strains, such as pyomyositis, osteomyelitis, necrotizing
fasciitis, severe pneumonia, and sepsis, have also been reported
[3–7]. CA-MRSA strains share a common pulsed field gel
electrophoresis (PFGE) pattern, show greater susceptibility to
most non-b-lactam antibiotics, and carry staphylococcal cassette
chromosome mec (SCCmec) type IV or V elements; these
characteristics are not typical of healthcare-associated MRSA
(HA-MRSA) strains [1].
In recent years, CA-MRSA has emerged as an important cause
of healthcare-associated and nosocomial bacteremia in many
countries [8–10]. In contrast to the US and Europe, the major
CA-MRSA strains in Taiwan are ST59, SCCmec IV or ST59,
SCCmec VT; the major clone in nosocomial MRSA infections in
Taiwan is SCCmec III: ST239, followed by SCCmec II: ST 5 [11–
16]. Molecular epidemiological definitions, based on staphylococ-
cal cassette chromosome mec (SCCmec) typing and phylogenetic
analysis of MRSA isolates, are considered the most reliable way to
distinguish between HA-MRSA and CA-MRSA [17]. In a study
of MRSA bacteremia by Seybold et al., CA-MRSA strains (as
defined by PFGE) were associated with injection drug use and with
skin and soft tissue infection [8]. In their study of CA-MRSA
strains defined by antibiogram phenotype, Popovich et al.
concluded that demographic data and risk factors could not
reliably distinguish patients infected with CA-MRSA strains from
those infected with HA-MRSA strains [9].
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9489SCCmec II and III, which are larger elements, may not be suited
to CA-MRSA strains; these elements show a different distribution
of antibiotic resistance genes and toxin genes compared to SCCmec
IV and V [17]. In this study, we compared the demographic
characteristics, clinical features, and outcomes of patients with
MRSA isolates with different SCCmec types.
Materials and Methods
Patient Selection
This study was conducted according to the principles expressed
in the Declaration of Helsinki and was approved by the
Institutional Review Board (No. 200705068R) of National Taiwan
University Hospital (NTUH), Taipei, Taiwan. The Institutional
Review Board waived the need for informed consent from
participants because the study involved very minimal risk to the
subjects, did not include intentional deception, and did not involve
sensitive populations or topics; this waiver does not adversely affect
the rights and welfare of the subjects.
NTUH is a university hospital with 2500 beds that provides
primary and tertiary care in northern Taiwan. From January 1
through December 31, 2006, all patients age .16 years with
MRSA bacteremia admitted to NTUH were identified from
information in a laboratory database.
Data Collection
All patients were evaluated using a structured form. The clinical
course of the infection and the infection foci were evaluated and
recorded based on information supplied by primary care
physicians and medical records. Diagnosis of the infection focus
was based on clinical, bacteriological, and radiological results. The
infection was considered ‘‘deep-seated’’ if any of the following
were present: infective endocarditis, mycotic aneurysm, osteomy-
elitis, septic arthritis, pyomyositis, necrotizing pneumonia/empy-
ema, or abscess formation in any deep organ, such as the liver or
kidney. Modified Duke criteria were used to evaluate infective
endocarditis [18]. Catheter-related bacteremia was defined by a
semi-quantitative culture of the vascular catheter tip that yielded
more than 15 MRSA colonies in the absence of other sources of
bacteremia [19]. The other sites of infection at the onset of
bacteremia were defined according to the US Centers for Disease
Control and Prevention criteria [20]. If no infection focus could be
identified, the bacteremia was classified as primary bacteremia.
The following data were recorded for each patient: age, sex,
underlying illness, hospitalization history or outpatient department
involvement within the previous year, existence of a percutaneous
device catheter, time from admission until a MRSA-positive
culture, initial laboratory findings, and outcome.
‘‘Health care–associated’’ was defined using previously pub-
lished definitions [8,9], which include hospital-onset infection or
the presence of any of the following HA-MRSA risk factors within
the year prior to the index culture: (1) residence in a longterm care
facility, (2) prior admission to an acute care facility (3) use of
central intravenous catheters or longterm venous access devices,
(4) use of urinary catheters, (5) use of other longterm percutaneous
devices (6) prior surgical procedures, and/or (7) need for any form
of dialysis [8,9].
Microbiological Laboratory Procedures
Identification of S.aureus was based on colony morphology,
Gram staining, a positive catalase reaction, slide agglutination test
results (bioMe ´rieux, Marcy l’Etoile, France), and/or results
obtained with the Phoenix system (Becton Dickinson, Sparks,
MD, USA). Antibiotic susceptibility testing for S. aureus in this
study included oxacillin, vancomycin, minocycline, levofloxacin,
ciprofloxacin, tetracycline, trimethoprim/sulfamethoxazole, gen-
tamicin, clindamycin, and rifampin and was performed according
to standard microbiological methods [21]. Resistance to oxacillin
was confirmed by PCR for the mecA gene. The presence of the
PVL gene lukF-lukS was determined by PCR using a primer that
was described previously [22], and the presence of 10 staphylo-
coccal enterotoxin virulence genes (sea, seb, sec, sed, see, seg, seh,
sei, sej, and tst) was also determined by PCR using the protocol of
Jarraud et al. [23]. The presence of the SCCmec elements (I–V)
and the mecA gene was determined by methods described
previously [14,24–26]. Analysis of the polymorphic X-region of
the protein A gene (spa) and multilocus sequence typing (MLST)
for the major pulso type was performed as described previously
[27–28]. Analysis of PFGE patterns was performed using
GelCompar software (Applied Maths, Austin, TX, USA). We
performed spa typing and PFGE typing of all isolates, but only
performed MLST on major pulsotypes in different SCCmectypes.
Statistical Analysis
Mean values and standard deviations were calculated for
continuous variables. Percentages were used for categorical
variables. For univariate analysis, SCCmec types were compared
using the chi-square test or Fisher’s exact test as indicated for
categorical variables and the analysis of variance (ANOVA) test
with least-significant-difference post-hoc tests for continuous
variables. Due to their similar biological features, we considered
SCCmec II and III to be one group and SCCmec IV and SCCmec V
to be another group. The associations between potential risk
factors and SCCmec II/III or SCCmec IV/V in patients with
MRSA bacteremia were also investigated using univariate and
multivariate logistical regression. Crude and adjusted odds ratios
(ORs) and the corresponding 95% confidence intervals (CIs) were
calculated. Cumulative survival after the day of the first MRSA-
positive blood culture was calculated using the Kaplan-Meier
method. Differences in cumulative survival for patients with
different SCCmec types were tested with the log-rank test. The
effect of infection with CA-MRSA on outcome was evaluated
using a multivariate Cox proportional hazards regression model
adjusted for age, sex, and underlying comorbidities. The data were
analyzed using SPSS software for Windows (Release 15.0; SPSS,
Chicago, IL).
Results
Patients, Risk Factors, and Clinical Features
During the study period, there were 159 consecutive adult
patients with MRSA bacteremia from whom isolates were
collected for microbiological analysis (101 men, 63.5%; 58
women, 36.5%). Twelve patients from whom isolates were not
collected were excluded from the study. There were no
differences between the study group and the excluded group
in terms of sex, age, and ward distribution. The mean age of the
159 adult patients was 67.3616.5 years. The MRSA SCCmec
types were as follows: 30 SCCmec II (18.9%), 87 SCCmec III
(54.7%), 22 SCCmec IV (13.8%), and 20 SCCmec V( 1 2 . 6 % ) .A l l
SCCmec V isolates belonged to SCCmec type VT [13]. Seven
patients matched the criteria for CA-MRSA bacteremia (4.4%),
including 4 (57.1%) MRSA isolates with SCCmec IV and 3
(42.9%) with SCCmec V. In the remaining 152 (95.6%) patients
with HA-MRSA bacteremia, 29 (18.2%) patients had commu-
nity-onset infections and 123 (77.4%) had hospital-onset
infections. For 29 patients with community-onset HA-MRSA
bacteremia, the SCCmec type distribution was as follows: 4
SCCmec in MRSA Bacteremia
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IV, and 6 (20.7%) SCCmec V. In 123 patients with hospital-
onset HA-MRSA bacteremia, the distribution of SCCmec types
was 26 (21.1%) SCCmec II, 76 (61.3%) SCCmec III, 10 (8.1%)
SCCmec IV, and 11 (8.9%) SCCmec V. The distribution of each
SCCmec type in a heathcare setting (either community-onset or
hospital-onset, with or without healthcare associated factor) is
shown in Figure 1.
MRSA Bacteremia Patient Characteristics Associated with
Specific MRSA SCCmec Types
Table 1 summarizes the demographic data and comorbidities of
all patients. The mean age of patients with MRSA SCCmec V (56.9
years) was significantly lower than that of patients with MRSA
SCCmec II (69.9) and MRSA SCCmec III (69.0) (P,0.05). MRSA
carrying SCCmec II/III was more likely to occur in the ICU, and
Figure 1. The distribution of SCCmec: community-onset (CO) or hospital-onset (HO) and healthcare-associated (HA) factor.
doi:10.1371/journal.pone.0009489.g001
Table 1. Comparison of demographic data and comorbidities of MRSA bacteremia patients with different SCCmec types.
Characteristic, n (%)
SCCmec II
n=30
SCCmec III
n=87
SCCmec IV
n=22
SCCmec V
n=20
Total
n=159 P
Sex, male 20 (66.7) 56 (64.4) 12 (54.5) 13 (65.0) 101 (63.5) 0.816
Age, mean years 6 SD 69.9614.9 69.0615.9 66.6615.6 57.0619.4 67.3616.5 0.02
Community onset 4 (13.3) 11 (12.6) 12 (54.5) 9 (45.0) 36 (22.6) ,0.001
ICU onset 15 (50) 40 (46) 2 (9.1) 0 (0) 57 (35.8) ,0.001
Length of hospital say before index culture
mean days 6 SD, median (range)
35.9633.1
28 (0–157)
50.7671.3
26 (0–360)
6.769.0
3 (0–33)
11.1612.2
10.5 (0–39)
36.8657.6
19.0 (0–360)
0.001
Comorbid condition
No underlying disease 0 (0) 0 (0) 1 (4.8) 2 (10) 3 (1.9) 0.017
Diabetes mellitus 7 (23.3) 35 (40.2) 2 (9.1) 6 (30.0) 50 (31.4) 0.027
Cancer 10 (33.3) 25 (28.7) 5 (22.7) 11 (55) 51 (32.1) 0.106
Liver cirrhosis 2 (6.7) 12 (13.8) 1 (4.5) 4 (20) 19 (11.9) 0.375
End-stage renal disease 3 (10) 16 (18.4) 4 (18.2) 1 (5) 24 (15.1) 0.409
Cerebrovascular disease 5 (16.7) 24 (27.6) 3 (13.6) 2 (10) 34 (21.4) 0.242
Charlson comorbidity score $3 17 (56.7) 55 (63.2) 10 (45.5) 11 (55) 93 (58.5) 0.490
Bed-ridden status 7 (23.3) 28 (32.2) 3 (13.6) 1 (0.5) 39 (24.5) 0.035
Recent surgery 10 (33.3) 16 (18.4) 0 (0) 2 (10.0) 28 (17.6) 0.009
doi:10.1371/journal.pone.0009489.t001
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community (P,0.05). The time from admission to the first MRSA-
positive blood culture for patients infected with isolates with the
SCCmec III element (mean/median, 50.7/26 days) was signifi-
cantly longer than for patients infected with isolates carrying
SCCmec IV or V (mean/median, 6.7/3 days for SCCmec IV; 11.1/
10.5 days for SCCmec V) (P,0.05). Compared to patients with
SCCmec V isolates, MRSA bacteremia patients with SCCmec III
isolates were more likely to be bedridden, but their infections were
less likely to be associated with underlying disease (P,0.05).
Patients with SCCmec III isolates were also more likely to have
diabetes compared to those with MRSA SCCmec IV (P,0.05).
Compared to patients with SCCmec IV isolates, those with MRSA
carrying SCCmec II were more likely to have had surgery within
the previous three months (P,0.05)
Table 2 shows the clinical characteristics and outcomes of
bacteremia patients infected with MRSA with different SCCmec
types. In terms of infection sites, MRSA with SCCmec IV was more
often associated with superficial skin and soft tissue infections than
MRSA with SCCmec II (P=0.015). In addition, patients with
MRSA carrying SCCmec IV were significantly more likely to have
non-prosthetic septic arthritis/osteomyelitis (P,0.001) and deep-
seated infections not related to surgery or prosthesis (P=0.008)
compared to MRSA bacteremia patients with SCCmec II and
SCCmec III isolates.
SCCmec II/III vs. SCCmec IV/V
In subsequent analyses, we grouped patients with SCCmec II and
SCCmec III isolates together for comparison with patients with
SCCmec IV and SCCmec V isolates. In univariate analysis, age, ICU
onset, length of stay before index culture, diabetes mellitus, bedridden
status, recent surgery, and catheter-related infection were associated
with recovery of SCCmec II/III isolates (Table 3). Community onset,
skin and soft tissue infection, and deep-seated infection (not related to
surgery/prosthesis) were risk factors associated with isolates carrying
SCCmec IV/V (Table 3). Multivariate analysis revealed four
independent factors associated with patients infected by MRSA
carrying SCCmec II/III: ICU onset (OR, 16.82; 95% CI, 3.52–
80.15), length of stay before index culture (OR 1.07; 95% CI, 1.03–
1.10), diabetes mellitus (OR, 4.51; 95% CI, 1.51–13.42), and
bedridden status (OR, 5.90; 95% CI, 1.61–21.61) (Table 3).
In univariate analysis, MRSA bacteremia patients with SCCmec
II/III isolates had more catheter-related infections and had more
often had recent surgery, and patients with SCCmec IV/V isolates
had more skin and soft tissue infections and more deep-seated
infections. However, these associations failed to reach significance
in multivariate analysis.
Mortality Analysis
Figure 2 shows the Kaplan-Meier survival curves for MRSA
bacteremia patients with isolates carrying different SCCmec types.
Table 2. Comparison of clinical characteristics and outcomes of MRSA bacteremia patients with different SCCmec types.
Clinical syndrome,n (%)
SCCmec II
n=30
SCCmec III
n=87
SCCmec IV
n=22
SCCmec V
n=20
Total
n=159 P
Infection focus*
1
Primary bacteremia 6 (20.0) 15 (17.2) 6 (27.3) 5.(25.0) 32 (20.1) 0.695
Skin and soft tissue 0 (0) 6 (6.9) 5 (22.7) 3.(15.0) 14 (8.8) 0.015
Central catheter related infection 13 (43.3) 35 (40.2) 7 (31.8) 3 (15.0) 58 (36.5) 0.152
Surgical site or prosthetic infection 5 (16.7) 12 (13.8) 1 (4.5) 0 (0) 18 (11.3) 0.187
Pneumonia 11 (36.7) 27 (31.0) 3 (13.6) 6 (30) 47 (29.6) 0.326
Deep-seated infection*
2 2 (6.7) 3 (3.4) 6 (27.3) 3 (15.0) 14 (8.8) 0.004
Endocarditis 1 (3.3) 2 (2.3) 3 (13.6) 1 (5.0) 7 (4.4) 0.140
Septic arthritis and osteomyelitis 0 (0) 0 (0) 4 (18.2) 1 (5.0) 5 (3.1) ,0.001
Necrotizing pneumonia and empyema1 (3.3) 2 (2.3) 0 (0) 2 (10) 5 (3.1) 0.256
Outcome
Persistent bacteremia*
3 4 (13.3) 5 (5.7) 1 (4.5) 1 (5.0) 11 (6.9) 0.532
7-day mortality 6 (20.0) 8 (9.2) 0 (0) 0 (0) 14 (8.8) 0.002
30-day mortality 12 (40) 26 (29.9) 4 (18.2) 8 (40.0) 50 (31.4) 0.309
*
1Some patients had more than one focus of infection.
*
2Deep-seated infection not related to surgery or prosthesis.
*
3Persistent bacteremia (.7 days).
doi:10.1371/journal.pone.0009489.t002
Table 3. Results of univariate and multivariate logistic
regression analyses (SCC mec II/III isolates vs. SCCmec IV/V
isolates).
Univariate OR
(95% CI)
Multivariate OR
(95% CI)
ICU onset 17.74 (4.10–76.84) 16.82 (3.52–80.15)
Recent surgery 5.71 (1.29–25.24)
Bedridden 4.06 (1.35–12.23) 5.90 (1.61–21.61)
Diabetes 2.38 (1.01–5.61) 4.51 (1.51–13.42)
Catheter-related infection 2.23 (1.00–4.95)
Length of hospital say before
index culture
1.07 (1.04–1.11) 1.07 (1.03–1.10)
Age 1.03 (1.01–1.04)
Skin and soft tissue infection 0.23 (0.08–0.71)
Deep-seated infection 0.16 (0.05–0.52)
Community-onset 0.15 (0.07–0.33)
doi:10.1371/journal.pone.0009489.t003
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60% for patients with SCCmec II, III, IV, and V isolates,
respectively. There was no significant difference in survival
(P=0.293, log-rank test). The 30-day cumulative survival was
67.5% for patients with SCCmec II/III isolates and 71.4% for
patients with SCCmec IV/V isolates; no significant differences
emerged (P=0. 403, log-rank test)(Figure 3).
To determine whether the SCCmec type would independently
affect 30-day mortality, we performed Cox-regression analysis by
controlling for age, sex, and comorbidity (Charlson score). After
Figure 2. Thirty-day Kaplan-Meier survival curves for MRSA bacteremia patients according to SCCmec type.
doi:10.1371/journal.pone.0009489.g002
Figure 3. Thirty-day Kaplan-Meier survival curves for MRSA bacteremia patients: SCCmec II/III vs. SCCmec IV/V.
doi:10.1371/journal.pone.0009489.g003
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day mortality of patients with SCCmec IV/V isolates was not
significantly higher than that of patients with SCCmec II/III isolates
(adjusted hazard ratio, 0.793; 95% CI, 0.406–1.547; P=.496).
Genotype, Antimicrobial Susceptibility, and Virulence
Gene Profile of the MRSA Isolates
Table 4 shows the genotype, antibiotic susceptibility, and
virulence gene profile of isolates with four different SCCmec types.
The genotypes of the HA-MRSA strains (SCCmec II and III) were
more homogeneous (the same identical spa type and pulsotypes)
than those of the CA-MRSA strains (SCCmec IV and V). Figure 4
shows the PFGE of MRSA isolates containing 4 different SCCmec
types. The main pulsotypes carried with SCCmec II were ST5, spa
t002, and agr 2 and were positive for the sec, seg, sei, and tst genes.
The main strain carrying SCCmec IV and V was ST59 and was
positive for spa t437, agr 1, and seb. The major differences in
virulence gene profiles and antibiotic susceptibility between
SCCmec IV and SCCmec V isolates were the pvl carrier rate (9%
vs. 85%) and gentamicin susceptibility (36% vs. 90%), respectively.
The major strain carrying SCCmec III was spa ST239 and was
positive for spa t037, agr1, and sea. Isolates with SCCmec III were
often multi-drug resistant except for rifampin.
Discussion
We conducted a large one-year retrospective study in a medical
center in Taiwan that included 159 consecutive adult patients with
MRSA bacteremia. We recorded bacterial genotyping results,
antibiotic susceptibility, and virulence gene profiling results for
each patient. In this study, the percentage of MRSA bacteremia
patients with community-onset, healthcare-associated MRSA with
SCCmec IV/V was 48%; among patients with hospital-onset,
healthcare-associated MRSA, the frequency was 17%. This
finding is similar to those of previous studies in US populations
that found that CA-MRSA strains (USA 300) are an important
cause of healthcare-related infections [8–10,29,30]. We compared
the demographic characteristics, risk factors, and outcomes of
adult MRSA bacteremia patients from whom strains with different
SCCmec types were isolated (SCCmec II, III, IV, and V).
Microbiological study of the isolates showed that the major clones
of CA-MRSA strains in Taiwan (SCCmec IV/V, spa t437, ST59
with or without the pvl gene) or HA-MRSA strains in Taiwan
(SCCmec III, spa t037, ST239 and SCCmec II, spa t002, and ST5
with the tst gene) differed from those in the United States and
Europe. In addition, we found the demographic and clinical
characteristics of patients with MRSA bacteremia differed
according to specific SCCmec subtype.
Two recent studies of MRSA bacteremia used the USA300
PFGE pattern and typical antibiotic phenotype for differentiating
CA-MRSA and HA-MRSA strains [8–9]. The association we
identified between SCCmec II/III and ICU onset and length of stay
before index culture was similar to results from previous studies [8–
10,30]. Previous studies identified a trend between a longer hospital
stay before index culture and greater risk of ICU admission in HA-
MRSA bacteremia patients [8,9]. Our cohort also showed longer
hospitalization beforeindex culture and more casesof ICUonset.In
our study, the number of days the patient was bedridden and
diabetes mellitus were other risk factors associated with SCCmec II/
III isolates. SCCmectypes IV and V are considerably smaller than
Table 4. Molecular typing, antimicrobial susceptibility, and virulence genes of MRSA isolates with different SCCmec types.
SCCmec II
n=30
SCCmec III
n=87
SCCmec IV
n=22
SCCmec V
n=20
Major spa type (%)
MLST*
t002 (97%)
ST5
t037 (93%)
ST239
t437 (68%)
ST59
t437 (75%)
ST59
Major agr type (%) agr 2 (93%) agr 1 (98%) agr 1 (77%) agr 1 (85%)
Antibiotic susceptibility profile
Oxacillin MIC$128 mg/mL (%) 100 99 0 0
Vancomycin MIC=2 mg/mL (%) 7 30 0 0
Susceptible rate to non-b-lactam (%)
Erythromycin 0 0 9 10
Clindamycin 0 18 23 15
Gentamicin 0 1 36 90
Levofloxacin 0 0 100 90
Ciprofloxacin 0 0 100 90
Trimethoprim-sufamethoxazole 100 0 100 100
Minocycline 100 62 91 100
Tetracycline 100 0 41 40
Rifampin 53 83 96 80
Virulence gene
pv l (%) 0 0 9 85
Enterotoxin gene (sea-sej,tst) sec:7 7 %
seg: 100%
sei: 100%
tst: 87%
sea:8 7 %
seb:2 %
seg:1 %
sei:1 %
seb: 68%
sec:9 %
seg: 23%
sei:2 3 %
seb: 80%
seg: 10%
sei: 10%
sej: 10%
*We only performed MLST on strains from major pulsotypes for the different SCCmec types.
doi:10.1371/journal.pone.0009489.t004
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MRSAstrains do not survive well in the community setting and that
antibiotic selective pressure or cross-transmission in the hospital
were needed for the survival of HA-MRSA strains [17].
Little has been published regarding the role or association of
specific MRSA genotypes with particular presentations. Fowler et
al. showed that MRSA ST30 was associated with a significant trend
towards higher levels of hematogenous complications [31]. Edge-
worth et al. suggested that the ST239 strain was associated with an
increased rate of vascular access device-related bacteremia [32]. In
univariate analysis in this study, the bacteremia patients with HA-
MRSA strains (t002, ST5 and t037, ST239) had more catheter-
related infections, and patients with CA-MRSA strains (mainly spa
t437 and ST59) showed a trend towards more skin and soft tissue
infections and deep-seated infections; however, neither association
reached significance in multivariate analysis. Our findings support
previous reports that CA-MRSA strains are highly associated with
skin and soft tissue infection, osteomyelitis, and necrotizing
pneumonia, although the CA-MRSA strain in Taiwan was not
USA300 [1–5]. Although our investigation only included patients
withMRSA bacteremia, itextendedthe finding that certainS.aureus
genotypes are more likely to be associated with some clinical
syndromesorwithinfectionseverity[31–33].Several studiessuggest
that CA-MRSA strains harboring the smaller SCCmec type IV
element grow faster and achieve higher infection burdens than
nosocomial MRSA strains [34–38]. In agreement with this
observation, we found that there were more deep-seated infections
involving MRSA with SCCmec IV/V than other subtypes.
Figure 4. Pulsed-field gel electrophoresis of different SCCmec types; red indicates the major pulsotype.
doi:10.1371/journal.pone.0009489.g004
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more lethal than SCCmec II/III isolates. This may be due to more
severe comorbidities and more isolates with high vancomycin MIC
(MIC=2) in patients with MRSA carrying SCCmec II/III.
Our study had some limitations. First, the SCCmec and genotype
distribution was different than that reported in other parts of the
world, so our results cannot be generalized to populations in which
the distribution of CA-MRSA and HA-MRSA strains differs from
Taiwan. Second, differences in infection presentation and outcome
may be explained by factors other than SCCmec genotype, such as
virulence genes, antibiotic MIC for the bacterial isolates, adequate
infection drainage, and empirical vancomycin therapy. The study
size may be too small to address associations between genotype and
clinical syndromes or severity.
In conclusion, in this study of 159 adult MRSA bacteremia
patients, specific demographic and clinical risk factors were found
to predict recovery from bacteremia caused by MRSA with
different SCCmec types. MRSA isolates carrying SCCmec II/III
were found more frequently in patients with significant comor-
bidities and prolonged hospitalization. Community onset, skin and
soft tissue infection, and deep-seated infection best predicted
MRSA isolates carrying SCCmec IV/V.
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